Q1FY22 Result Update - Miss on weak US, ARV; Unfocussed M&A may impact proposed split of Inj biz - Downgrade to 'HOLD'
USFDA completed inspection of Unit-1 with 7 observations from Form 483. We downgrade ARBP's rating to Hold' from Buy' with revised TP of Rs795 (earlier Rs1,139) driven by a) cut in sales estimates by 13%/9% in...